Progyny, Inc. (PGNY) Stock Price & Analysis
Progyny, Inc. (PGNY) fell 0.35% to USD 25.83 as of June 10, 2026 at 02:28 UTC, according to Nexqual real-time market data.
PGNY last closed at USD 25.92; the session ranged USD 25.7–26.24 on volume of 1,525,760 shares. Market capitalization is $2.02B, with a 52-week range of USD 16.1–28.75 (NMS). Source: Nexqual, June 10, 2026 at 02:28 UTC.
Key Statistics (as of June 10, 2026 at 02:28 UTC)
| Price | USD 25.83 |
|---|---|
| Change | ▼ 0.35% (down) |
| Previous Close | USD 25.92 |
| Open | USD 25.84 |
| Day Range | USD 25.7 – 26.24 |
| 52-Week Range | USD 16.1 – 28.75 |
| Volume | 1,525,760 shares |
| Market Cap | $2.02B |
| Exchange | NMS |
Technical Analysis (PGNY)
Nexqual's technical model rates PGNY "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:28 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 68.76 (neutral) |
| vs SMA50 | Above (USD 20.83) |
| MACD | 1.39 (positive) |
Analyst Ratings (PGNY)
Wall Street analysts rate PGNY "Strong Buy" based on 11 analysts, with a mean price target of USD 29.73 (range USD 26–31), per Nexqual as of June 10, 2026 at 02:28 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 29.73 |
| High Target | USD 31 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (PGNY)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.52 |
| Revenue Estimate | $348.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.5 vs est 0.44 ▲ beat |
| 2025-12-31 | USD 0.48 vs est 0.4 ▲ beat |
| 2025-09-30 | USD 0.45 vs est 0.39 ▲ beat |
| 2025-06-30 | USD 0.48 vs est 0.43 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:28 UTC.
Financials & Fundamentals (PGNY)
| Total Revenue | $1.29B |
|---|---|
| Revenue Growth (YoY) | +1.40% |
| Gross Margin | +24.11% |
| Operating Margin | +10.77% |
| Profit Margin | +5.24% |
| ROE | +14.94% |
| Debt / Equity | 6.21 |
| Current Ratio | 2.13 |
| Total Cash | $225.11M |
| Total Debt | $27.28M |
| Free Cash Flow | $200.21M |
Source: Nexqual, June 10, 2026 at 02:28 UTC.
Financial Health Score (PGNY)
Nexqual rates Progyny, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:28 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 24%, operating 11% |
| Balance Sheet | Strong — $225M cash vs $27M debt, net cash position |
| Cash Flow | Strong — FCF $200M, 16% margin |
| Efficiency | Mixed — ROE 15%, ROA 9.1% |
Ownership (PGNY)
| Insider Ownership | +1.94% |
|---|---|
| Institutional Ownership | +112.20% |
| Shares Outstanding | 78.33M |
| Float | 71.61M |
| Short % of Float | +9.09% |
Source: Nexqual, June 10, 2026 at 02:28 UTC.
Leadership (PGNY)
Progyny, Inc. is led by Peter Anevski (age 58), CEO & Director, per Nexqual as of June 10, 2026 at 02:28 UTC.
| CEO & Director | Peter Anevski (age 58) |
|---|---|
| Executive Chairman | David J. Schlanger (age 66) |
| Chief Financial Officer | Mark S. Livingston (age 59) |
| Chief Operating Officer | Melissa B. Cummings (age 55) |
| Chief Product Officer | Geoffrey Clapp (age 51) |
Major Backers & Investors (PGNY)
Notable institutional backers of Progyny, Inc. include FMR, LLC, Fidelity, Ameriprise Financial, Inc., according to Nexqual as of June 10, 2026 at 02:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.3% |
| Fidelity | 4.06% |
| Ameriprise Financial, Inc. | 3.61% |
| Fort Washington Investment Advisors, Inc. | 3.44% |
| Wellington Management | 2.92% |
| Morgan Stanley | 2.92% |
| Soleus Capital Management, L.P. | 2.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.81% |
| Vanguard Group | 19.03% |
| State Street | 3.93% |
Source: Nexqual, June 10, 2026 at 02:28 UTC.
From Progyny, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our cybersecurity risk management program incorporates industry-standard frameworks, policies and practices designed to protect the security of our technology infrastructure and sensitive information.
Partnerships
- We have experienced and may in the future experience fluctuations in our financial results, making it difficult to project future results, and if we fail to meet the expectations of securities analysts or investors with respect to our results of operations, our stock price and the value of your investment could decline.
- Share Repurchase Program On November 5, 2025, the Company announced the November 2025 share repurchase program (the "November 2025 share repurchase program") of up to $200 million of shares of common stock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INMD | InMode Ltd. | USD 13.56 | ▲ 0.15% |
| SPT | Sprout Social, Inc | USD 6.96 | ▼ 3.73% |
| OM | Outset Medical, Inc. | USD 4.69 | ▲ 2.4% |
| TXG | 10x Genomics, Inc. | USD 30.59 | ▼ 1.45% |
| HCAT | Health Catalyst, Inc | USD 1.71 | ▼ 11.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:28 UTC. This page is informational and not investment advice.